iiinova — where your digital self keeps evolving

Reposted by Manzoor khan

Ajay Major, MD, MBA @majorajay.bsky.social · 27/11/2024

Ibru+ven x 16➡️ibru+obinu x 6 if MRD+ (if uMRD-, obs) #ASH24: - 84 pts, 7% TP53mut, 57% very high CLL-IPI - 21% uMRD➡️obs: 2-yr PFS 94% - 79% MRD+➡️IO intensification: 60% achieved subsequent uMRD, 2-yr PFS 92% 60% of all pts achieved uMRD. Time-limited tx strategies ftw! #leusm

021

Reposted by Manzoor khan

Muzaffar Qazilbash @transplantdoc.bsky.social · 22/11/2024

#ASH24 Circulating Tumor Cells (CTC) as a biomarker for TE NDMM in Perseus trial (D-VRd vs. VRd) -CTC is an independent prognostic factor -HR cytogenetics + CTC => dismal outcome #mmsm #bmtsm ash.confex.com/ash/2024/web...

ash.confex.com

Paper: Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Indu...

042

Reposted by Manzoor khan

Stephen Liu @stephenvliu.bsky.social · 19/11/2024

ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for #EGFR NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC. #LCSM ascopubs.org/doi/10.1200/...